UNSPSC 51142562: Piribedil monomethanesulfonate

This classification denotes a dopamine agonist with the molecular formula C16H18N4O2.CH4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1U37NGM6KK, chemically known as 2-(4-(1,3-benzodioxol-5-ylmethyl)piperazin-1-yl)pyrimidine, methanesulfonic acid, but more generally known as piribedil monomethanesulfonate, which bears US NIH Compound Identifier 198284. European Medicines Agency schedules piribedil monomethanesulfonate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09908MIG.

Most nations, for tariff purposes, schedule piribedil monomethanesulfonate under HS 29349990. SMILES: CS(=O)(=O)O.C1CNC(NC1)N2CCN(CC2)CC3CCC4C(C3)OCO4.

UNSPSC 51142562 Piribedil monomethanesulfonate is a Commodity code that nominally identifies a specific pharmaceutical active ingredient, but recent state and local procurement activity under this code shows little alignment with that narrow classification. The most recent opportunities posted under this code involve procurement of finished pharmaceutical products and drug-deactivation systems rather than bulk chemical compounds — Seminole County, Florida sought naloxone and safe drug deactivation systems for community health programs; the Texas Health and Human Services Commission issued a market-intelligence RFI on direct-to-manufacturer prescription programs; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) solicited generic multi-source pharmaceuticals and over-the-counter products through a cooperative purchasing vehicle. State and local buyers tagging opportunities under this code include county health agencies, state health departments, and cooperative purchasing consortia serving multiple state and local members.

Geographically, recent activity centers on Florida, Texas, and Minnesota, with MMCAP's cooperative reaching participating jurisdictions in Oregon as well. The most concrete opportunity on record is Seminole County's IFB60459723LAS, an invitation for bid due July 26, 2026, for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building; the contract includes a two-year initial term with a one-year renewal option and requires shipping to be included in the bid price. The Minnesota MMCAP RFP (S1070000015802) closed to questions on February 18, 2026, with proposals due March 26, 2026, for generic pharmaceuticals and OTC products to be distributed through three authorized wholesalers effective July 1, 2026, with evaluation weighted 75 percent on price competitiveness and the remainder on administrative compliance, EDI capability, and fixed pricing. The code shows limited recent activity directly tied to its nominal scope, suggesting that mislabeling or broad tagging of finished-product pharmaceutical procurements under a bulk-ingredient classification may explain the divergence.